placebo (unspecified)

DRUG6 trials

Sponsors

Organon and Co, Merck Sharp & Dohme LLC

Conditions

AsthmaDyslipidemiaGeneralized Anxiety DisorderHypercholesterolemiaProstate Cancer

Phase 2

A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)

CompletedNCT00703833

Merck Sharp & Dohme LLCGeneralized Anxiety Disorder

Start: 2002-09-30End: 2003-02-28Updated: 2015-11-02

Phase 3

Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)

CompletedNCT00418834

Organon and CoHypercholesterolemia

Start: 2007-01-31End: 2008-10-31Updated: 2024-05-14

Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)

WithdrawnNCT00664287

Merck Sharp & Dohme LLCDyslipidemia

Start: 2008-09-30Updated: 2015-04-09

A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

WithdrawnNCT00691899

Merck Sharp & Dohme LLCProstate Cancer

Start: 2008-09-30End: 2008-09-30Updated: 2016-08-12

A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907)

CompletedNCT00700661

Organon and CoAsthma

Start: 2001-01-31End: 2002-12-31Updated: 2024-08-15

Phase 4

Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)

CompletedNCT00652444

Organon and CoHypercholesterolemia

Start: 2003-09-30End: 2004-08-31Updated: 2022-02-18

Related Papers

Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years.

2014-01-139 citations